Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Status:
Terminated
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to establish toxicity and a maximum tolerated dose recommended
phase 2 dose of Clofarabine in combination with Etoposide and Mitoxantrone for therapy of
relapsed or refractory acute leukemias. The investigators will observe responses with these
therapy agents and assess the impact of Clofarabine interacting with Etoposide in induction
of DNA strand breaks.